Existing shareholders, including Kingray Capital and TigerYeah Capital, demonstrated their continued support through follow-on investments. Proceeds will be primarily used to accelerate the continuous R&D of gene-edited animal platforms, advance the commercialization of its fully human antibody rabbit platform, establish the AI-driven antibody drug screening platform, develop scaffold antibodies for complex targets, and support general corporate operations as well as team expansion.
Immunocan has established a robust collaborative network with leading domestic and international pharmaceutical companies, including several Global Top 10 MNCs. The industrial value of its platforms has been rigorously validated by these tier-one partners. Meanwhile, the company is actively expanding diversified application scenarios for its platform technologies with multiple biotechnology enterprises.
Dr. Jiwei Zhang, Founder of Immunocan, stated: “We are deeply grateful for the trust and support of our new and existing investors. This RMB 250 million Series A financing is an important milestone for Immunocan, serving as a key driver for our transformation and strategic advancement. Moving forward, we will leverage our core multi-species antibody discovery technologies to expedite platform construction and pipeline development, to drive early-stage drug discovery in China's biopharma sector and broaden our network of global partners. Our goal is to build an internationally leading antibody discovery platform that delivers professional and efficient R&D solutions. With capital and technology as dual engines, we aim to achieve leapfrog growth and bring more breakthrough therapies to patients worldwide.”
Mr. Shan Fu, Managing Partner at Vivo Capital, commented: “Next-generation fully human model animal platforms, when integrated with AI-driven R&D capabilities, will become a formidable engine for innovative biologic drug development. Immunocan has already validated its platform's superiority through antibody screening for complex targets, earning high acclaim from MNCs. By leveraging rich data assets from diverse model animals, the company is poised to further integrate AI algorithms to build an intelligent discovery system, empowering the entire workflow from sequence generation to characterization and developability assessment. Vivo Capital is impressed by the company's differentiated MASIRT technology and its high-quality multi-species platforms. We look forward to collaborating closely with the team, utilizing Vivo’s global ecosystem to accelerate international expansion and the global landing of their innovative pipelines.”
Mr. Fu Dongping, Partner at Gaomai United Family Office, said: “Gaomai is optimistic about Immunocan’s proprietary MASIRT® technology, which enables ultra-large fragment cross-species in situ gene replacement and overcomes the humanization challenges of traditional rabbit monoclonal antibodies. The technology aims to elevate the global R&D level of therapeutic antibodies and drive innovative breakthroughs in China’s biopharmaceutical sector. By supporting pioneering tech firms like Immunocan, Gaomai helps family capital achieve high-quality inheritance while giving back to society.”
Mr. Leiwen Chen, Managing Partner at Kingray Capital, said: “Immunocan boasts a world-class gene-editing platform and robust molecule development capabilities. As an early investor that has participated in the company’s successive financing rounds in 2021, 2023 and 2025, we have witnessed the team’s remarkable progress and remain fully committed to supporting its efforts to develop clinically superior antibody drugs for patients worldwide.”
Dr. Tianrong Ji, Founder and General Manager of TigerYeah Capital, said: “Immunocan is a pioneer in large-fragment in situ replacement technology in China. With its proprietary artificial chromosome vectors, the company has built a globally competitive portfolio including fully human mouse, fully human heavy-chain-only mouse, fully human common light-chain mouse, and alpaca antibody mouse models. These platforms have achieved commercialization and gained wide market recognition, and the company has entered strategic cooperation agreements with multiple multinational corporations and leading domestic pharmaceutical firms. We look forward to the upcoming commercialization of its rare fully human antibody rabbit platform, which will further boost the overall efficiency of drug R&D.”
Mr. Lei Hong, Managing Director and Head of Healthcare at Lighthouse Capital, said: “It is an honor to have supported Immunocan through this financing. Since our first contact, we have witnessed the company’s platform technology consistently earn recognition from top-tier global pharmaceutical companies and frontline funds. In an era where drug R&D is returning to foundational innovation, Immunocan’s technological barriers and platform-level capabilities are exceptionally rare. We look forward to continuing our support, allowing this China-originated innovation platform to serve the global industry.”
About Vivo Capital
Vivo Capital is a premier global healthcare investment firm with a 30-year track record of building transformative companies. Since its founding in 1996, Vivo has evolved into a comprehensive investment platform spanning venture capital, growth equity, buyouts, and public markets. Managing $7.5 billion in assets across 16 USD and RMB funds, the firm has cultivated a portfolio of over 460 innovative companies worldwide. With an exclusive focus on the healthcare sector—ranging from biotech and pharma to devices and services—Vivo targets high-growth opportunities in the world’s most critical markets. Headquartered in Palo Alto, California, Vivo operates with a lean, expert team of over 70 professionals, maintaining key hubs in Beijing, Shanghai, Hong Kong, Taipei, and Singapore to bridge global innovation with local execution.
About Kingray Capital
Established in 2018, Beijing Xicheng Jinrui Equity Investment Fund Management Co., Ltd.(“Kingray Capital”) is a market-oriented professional investment institution with state-owned background. It was jointly initiated and established by Beijing Financial Street Capital Operation Group Co., Ltd., China State-owned Enterprise Structural Adjustment Fund Corporation Limited, and China Guoxin Fund Management Co., Ltd. The firm focuses on high-quality enterprises in sectors including digitalization, intelligence, green economy and healthcare.
About TigerYeah Capital
Founded in 2014, TigerYeah Capital is an independent venture capital under Tigermed. TigerYeah Capital focuses on equity investments in the medical and healthcare sector at the early and growth stages. The management team boasts profound industrial background, extensive industry resources and abundant investment experience. To date, it has deployed a total of over RMB 2 billion across more than 100 investment projects. Its investment portfolio covers medical devices, biomedicine, CRO, and health food. TigerYeah Capital creates value for the development of the medical and health industry in China and even the world by empowering the invested companies, and contributes to public health.